• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Two Parexel executives named to 2017 PharmaVOICE 100

Two Parexel executives named to 2017 PharmaVOICE 100

August 3, 2017
CenterWatch Staff

Parexel International, a global biopharmaceutical services provider, announced that Sy Pretorius, M.D., Senior Vice President and Chief Scientific Officer, and Evan Demestihas, M.D., RPh, Vice President, Worldwide Head of The Medical Affairs Company (TMAC), have been named to PharmaVOICE magazine’s list of the 100 most inspiring people in the life sciences industry. The honor, published in the July/August 2017 issue of PharmaVOICE, recognizes both leaders for their valuable contributions to the industry and dedication to improving patients’ lives, while also mentoring the next generation of industry leaders.

Dr. Pretorius has been with Parexel for more than 20 years in various international leadership roles. As Chief Scientific Officer, he collaborates closely with biopharmaceutical and medical device clients in designing and optimizing innovative drug/device development strategies and plans. He also leads several Parexel business units across three continents—including the Company’s global Early Phase business, Global Medical Services, Quantitative Clinical Development, as well as its Genomic Medicine unit.

Dr. Demestihas joined Parexel in February 2017, when the Company acquired TMAC, a leading full-service Contract Medical Organization (CMO). TMAC offers outsourced Medical Science Liaisons (MSLs), Clinical Nurse Educators (CNEs) and other field medical teams in addition to medical affairs consulting, medical information, and direct placement services. A 30-year veteran of the pharmaceutical industry, Dr. Demestihas has led TMAC from its founding in 2007. In 1997, Dr. Demestihas established the pharmaceutical industry’s first CMO, Science Oriented Solutions (SOS), and led the company for 10 years.

“We are proud that PharmaVOICE has recognized Dr. Sy Pretorius and Dr. Evan Demestihas among this year’s 100 most inspiring people in the life sciences industry. Their passion and dedication to drug development is felt throughout PAREXEL and beyond,” said Josef von Rickenbach, Chairman and CEO, Parexel. “Sy’s leadership in clinical trial innovation has helped Parexel expand our capabilities and service offerings to help our clients bring treatments to market faster and more efficiently. Evan is a pioneer in the medical affairs sector, who recognized a demand for medical affairs solutions across the industry and created a successful breakthrough business model. The leadership, innovation, and dedication that both Sy and Evan bring to Parexel inspire our global workforce each day.”

The annual PharmaVOICE 100 list honors a select group of leaders in the life sciences who positively impact their colleagues, peers, organizations, and the industry at large. These individuals are passionate, forward-thinkers who actively work to address industry challenges and trends.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing